Alpha 2.0
Login Register
» Authors » Sanxing Guo

Sanxing Guo

Explore the profile of Sanxing Guo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 21
Citations 214
Followers 0
Related Specialties
Oncology
General Medicine
Pharmacology
Top 10 Co-Authors
Xingya Li
Ningning Yan
Huixian Zhang
Shujing Shen
Siyuan Huang
Ziheng Zhang
Di Geng
Qianqian Guo
Suzhi Zhang
Linlin Li
Published In
Front Oncol
Front Pharmacol
Front Med (Lausanne)
Arch Virol
Cancer Res Treat
Affiliations
Soon will be listed here.
Recent Articles
1.
Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort study
Shen S, Li X, Guo S, Xu L, Yan N
Front Oncol . 2024 Jul; 14:1391828. PMID: 39040456
Introduction: This retrospective study evaluates the efficacy of camrelizumab combined with anlotinib versus chemotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC) undergoing second-line treatment. Methods: Data were sourced from...
2.
Corrigendum: The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience
Yan N, Guo S, Huang S, Zhang H, Li X
Front Oncol . 2024 Jun; 14:1412472. PMID: 38887239
[This corrects the article DOI: 10.3389/fonc.2024.1331128.].
3.
Case report: The effect of second-line vebreltinib treatment on a patient with advanced NSCLC harboring the MET exon 14 skipping mutation after tepotinib treatment
Huang S, Li L, Yan N, Zhang H, Guo Q, Guo S, et al.
Front Oncol . 2024 May; 14:1331387. PMID: 38706592
Background: Highly selective type Ib mesenchymal-epithelial transition gene (MET) tyrosine kinase inhibitors (TKIs) are the standard-of-care (SOC) therapy for previously untreated non-small cell lung cancer (NSCLC) harboring MET exon 14...
4.
The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience
Yan N, Guo S, Huang S, Zhang H, Li X
Front Oncol . 2024 Mar; 14:1331128. PMID: 38454923
Background: Furmonertinib is the standard treatment option in the first-line setting for advanced non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations in China. However, there...
5.
Efficacy of immune checkpoint inhibitors in advanced large cell neuroendocrine carcinoma of the lung: A single‑institution experience
Yan N, Guo S, Zhang Z, Shen S, Li X
Oncol Lett . 2024 Feb; 27(3):135. PMID: 38357477
Large cell neuroendocrine carcinoma (LCNEC) is a rare and highly invasive lung cancer subtype with an overall poor prognosis. Due to its low incidence rate and unusual pathological features, the...
6.
Efficacy of chemo-immunotherapy in metastatic -mutated lung cancer: a single-center retrospective data
Yan N, Zhang H, Guo S, Zhang Z, Xu Y, Xu L, et al.
Front Oncol . 2024 Feb; 14:1353491. PMID: 38357200
Background: The effectiveness of combining immune checkpoint inhibitors (ICIs) with chemotherapy in treating non-small cell lung cancers (NSCLCs) with mutations has not been sufficiently explored. Methods: We compiled data from...
7.
Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data
Yan N, Zhang H, Shen S, Guo S, Li X
BMC Cancer . 2024 Feb; 24(1):178. PMID: 38317126
Background: The impact of immune checkpoint inhibitors (ICIs) based treatments on non-small cell lung cancers (NSCLCs) with RET fusions remains poorly understood. Methods: We screened patients with RET fusions at...
8.
AIFM2 promotes hepatocellular carcinoma metastasis by enhancing mitochondrial biogenesis through activation of SIRT1/PGC-1α signaling
Guo S, Li F, Liang Y, Zheng Y, Mo Y, Zhao D, et al.
Oncogenesis . 2023 Sep; 12(1):46. PMID: 37735151
AIFM2 is a crucial NADH oxidase involved in the regulation of cytosolic NAD. However, the role of AIFM2 in the progression of human cancers remains largely unexplored. Here, we elucidated...
9.
Corrigendum: Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report
Yan N, Huang S, Li L, Guo Q, Geng D, Zhang H, et al.
Front Pharmacol . 2023 Aug; 14:1256801. PMID: 37576810
[This corrects the article DOI: 10.3389/fphar.2022.898623.].
10.
Corrigendum: Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report
Yan N, Zhang Z, Guo S, Shen S, Li X
Front Med (Lausanne) . 2023 Aug; 10:1256685. PMID: 37564044
[This corrects the article DOI: 10.3389/fmed.2023.1130012.].